UK Medtech Revolution – How can we secure the future of diagnostics?

Ronan Kitchen oversees Life Sciences and Healthcare vertical at logistics company Aramex UK, explains where it is needed Focus on promoting more flexible and localized supply chains to protect supplies and how to capitalize on the international interest the UK medical supply chain is attracting.

As 2023 unfolds, the UK medtech landscape has taken center stage, becoming a symbol of innovation and progress. Investments in this sector have yielded good returns, leading to a resurgence of domestic manufacturing for medical technologies. The momentum generated during the pandemic for more point-of-care testing (POCT) has catalysed significant advances in decentralized diagnostics, allowing patients to receive fast and reliable answers closer to home.

The demand for POCT kits has increased as patients now expect quick and accurate results for an increasing number of situations, from flu diagnosis to monitoring glucose levels. Healthcare and medical supply chains are taking advantage of this activity injection, with higher investments commensurate with this surge in demand. However, with interest rates reaching their highest levels in 15 years, it becomes increasingly important to invest strategically to protect our supply operations and maintain this extraordinary momentum.

Proud progress in UK diagnostics

The past 12 months have seen remarkable progress in the UK diagnostics sector, fueled by a sense of pride as we continue to use our prestigious manufacturing roots to drive research, development and supply for our thriving medtech industry. This strategic shift has not only provided a much-needed boost to the economy, but has also fostered more flexible and localized supply chains. These advantages include proximity to suppliers, shorter lead times, reduced emissions from logistics and transportation, and increased flexibility and adaptability.

Public and private support for the diagnosis

The diagnostics sector has received extensive government support to enhance its competitive advantage, with funds allocated for the innovation, manufacturing and export of future treatments. In particular, the Life Sciences Innovative Manufacturing Fund received £17 million in its first tranche, aimed at supercharging the R&D and innovation center network within UK manufacturing. The private sector has also shown enthusiasm and contributed £260 million, resulting in substantial funding of a total of £277 million.

Randox, one of the recipients of this fund, has received £36 million to modernize the manufacture of antibodies used in its clinical trials. Such investment has the potential to enhance the UK’s reputation as a leading manufacturing nation, making it more attractive to future foreign investment – ​​an invaluable advantage amid the current economic climate.

Unleash Manufacturing Skills

With the paddle to the metal for manufacturers developing components for the expanding catalog of PCOT diagnostic equipment, attention has now turned to the transportation and logistics (T&L) providers responsible for efficiently moving these critical components. The UK’s medical supply chain continues to attract international interest, partly due to long-term investment in research and development, exemplified by the notable production of the Oxford-AstraZeneca COVID-19 vaccine. Lessons learned from supply chain crises have led to the establishment of integrated supply chains that leverage local strengths.

Using specialist knowledge and manufacturing capabilities

Diagnostics requires expert knowledge to produce both large and small components that align with unmatched manufacturing capabilities. At every stage of the operation, the UK is leveraging its manufacturing capability, from setting up the necessary digital infrastructure, to building connected supply chains, to optimizing factory operations that produce key elements of diagnostic technologies.

investing in last mile success

To maintain the rapid pace set for UK diagnostics, we must now provide substantial support to the T&L network. Celebrating the achievements of our medtech industry is important, but it is equally essential to provide our own injection of investment to the T&L sector. By doing so, we can ensure that we play to our strengths and avoid any lapses in the final stages. Securing the momentum of this new era of advanced diagnostics depends on comprehensive support across the entire supply chain.